Imagenetix Launches Retail Branding Program; Former Pharmavite Executives To Spearhead Campaign

by Imagenetix on August 21, 2006

SAN DIEGO–(BUSINESS WIRE)–Aug. 21, 2006–Imagenetix, Inc. (OTCBB: IAGX – News) today announced a comprehensive nationwide retail branding program for its proprietary products. The first products to be branded under the program will be the company’s Celadrin®-based joint health formulas. These products, branded under the name Inflame Away(TM), will be exclusively marketed by Imagenetix and sold [...]

{ Comments on this entry are closed }

Imagenetix Appoints Former FDA, NIH Staffer to Guide IND Submission for Anti-Inflammatory Compound

by Imagenetix on June 26, 2006

SAN DIEGO–(BUSINESS WIRE)–June 26, 2006–Imagenetix, Inc. (OTCBB:IAGX – News) today announced it has engaged the services of Michael Hamrell, Ph.D., president of MORIAH Consultants, a regulatory affairs and clinical research consulting firm near Los Angeles. Dr. Hamrell, who has held leading positions within the FDA and NIH and served as a regulatory affairs and pharmaceutical [...]

{ Comments on this entry are closed }

Imagenetix Announces Positive Safety Studies on Anti-Inflammatory Compound, 1-TDC

by Imagenetix on June 1, 2006

SAN DIEGO–(BUSINESS WIRE)–June 1, 2006–Imagenetix Inc. (OTCBB: IAGX – News) today announced that its proprietary anti-inflammatory compound, 1-tetradecanol complex (1-TDC), intended for use in the treatment of periodontal disease and other widespread inflammatory conditions, has achieved expected results in important baseline acute toxicity studies.
In the first study, CD-1 mice were administered 1-TDC orally at a [...]

{ Comments on this entry are closed }

Imagenetix Announces 1-Tetradecanol Complex Acts to Inhibit Bacteria and Enzymes Associated with Oral Disease, Sepsis and Inflammation

by Imagenetix on May 8, 2006

SAN DIEGO–(BUSINESS WIRE)–May 8, 2006–Imagenetix (OTCBB:IAGX – News) today announced the successful completion of in vitro studies demonstrating the significant inhibitory function of its novel pharma compound, 1-tetradecanol complex (1-TDC). The main findings include:

1-TDC significantly inhibited the growth of Actinomyces viscosus, a microbe that has been shown to play a major role in oral microbial [...]

{ Comments on this entry are closed }

Imagenetix Commissions New Study to Evaluate Celadrin® Capsules for Patients with Knee Osteoarthritis

by Imagenetix on March 20, 2006

SAN DIEGO–(BUSINESS WIRE)–March 20, 2006–Imagenetix Inc. (OTCBB: IAGX – News), a company focused on joint health and joint health-related markets, today announced it has commissioned a new multi-site study to measure the effectiveness of its Celadrin® oral capsules for improving overall joint health in patients with osteoarthritis of the knee.
The primary purpose of this study [...]

{ Comments on this entry are closed }